Navigation Links
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
Date:1/26/2009

> isolates were 0.06, 0.12, and 4 micrograms/mL, respectively. Delafloxacin's MIC90 values against all MRSA including the quinolone-resistant MRSA strains was also 0.06 micrograms/mL.

"We are extremely encouraged by the final results of this third Phase 2 trial, which affirm delafloxacin's safety and show its broad spectrum activity in difficult-to-treat complicated skin infections," said Susan Froshauer, Ph.D., President and CEO of Rib-X Pharmaceuticals. "Delafloxacin proved to be the more active compound compared to tigecycline when evaluated against both Gram-positive and Gram-negative bacterial isolates from patients, including MRSA and quinolone-resistant MRSA and other organisms. Additionally, this drug has the potential for IV use in the hospital with an oral step down."

"Rib-X starts off 2009 extremely well positioned to proceed with advancing delafloxacin towards Phase 3 trials," continued Dr. Froshauer. "We not only have excellent Phase 2 results for one of our key compounds, but we also have the commitment of our investors, and we would like to thank them for their continued support."

Phase 2 Study Design and Results

This Phase 2 double-blind study evaluated the safety and efficacy of delafloxacin at two intravenous doses, 300 mg BID and 450 mg BID, compared to tigecycline (TYGACIL(R), Wyeth Pharmaceuticals), in adults with cSSSI. Treatment duration was 5 to 14 days. Of the 150 patients randomized in this trial, 68% were male; the mean age was 40+/-14.5 years. 36% had cellulitis, 31% had wound infections and 33% had abscesses. 111 (74%) patients had pathogens identified at baseline, with 96 identified as S. aureus.

The clinical cure rates in the Clinically Evaluable and Modified Intent-to-Treat populations are presented below:

                       Percent Clinical Cure at TOC
    Population      DFX 300 mg BID      DFX 450 m
'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
2. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
6. Axikin Pharmaceuticals Spins out of Actimis
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Cumberland Pharmaceuticals Appoints Lee Product Director
10. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
11. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Myriant Technologies, Inc. (Myriant), a privately-held, biotech ... the addition of J. Brian Ferguson to its ... is the former CEO and Chairman of Eastman ... the manufacture and sale of a broad portfolio ...
... Pa., March 2, 2011 Inovio Pharmaceuticals, Inc. (NYSE ... development of therapeutic and preventive vaccines against cancers and ... in a study of its DNA vaccine for foot-and-mouth ... preclinical data was highlighted by Dr. Niranjan Y. Sardesai, ...
... has put Canadian researchers at the National Institute for Nanotechnology ... World Records. Only one atom at its end point, ... object. It is made of Tungsten and fabricated using ... for its commercial potential., "We did not start out to ...
Cached Biology Technology:Myriant Technologies, Inc. Announces J. Brian Ferguson to Join Advisory Board 2Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 2Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 3Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 4Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 5Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 6
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... thought to be unique in toothed whales like dolphins ... University of Strathclyde. The research is challenging ideas ... and katydids hear, revealing the unexpected similarity to toothed ... Biological Sciences at The University of Auckland, with colleagues ...
... than their roots to take up water. They also ... of California, Berkeley, scientists have discovered. While ... otherwise dry areas, the scientists say that the clouds ... climate change. "The study highlights the vulnerability of ...
... holly leaves are a traditional Christmas decoration, from wreaths ... at a holly tree and while some leaves are ... Botanical Journal of the Linnean Society believe variations ... herbivore activity and molecular responses to environmental change. ...
Cached Biology News:Dolphin hearing system component found in insects 2Cloud forest trees drink water through their leaves 2Prickly holly reveals ability to adapt genetics to environmental change 2
MMP-1/8 (H-300)...
Gastric Carcinoma Marker [BY-1 (3H11)]...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: